HEALEY ALS Platform Trial

Weekly Q&A – Dec 1, 2022

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General










































Catherine Douthwright, PhD

Neuromuscular Clinical Research Program Director UMass Chan Medical School

Worcester, MA











Our team








Robert H. Brown Jr., MD, DPhil Margaret Ayo Owegi, DO Mehdi Ghasemi, MD, MPH Catherine Douthwright, PhD Hajar Houmani, DNP Reylyn Tanchiatco

The goal of the HEALEY ALS Platform Trial is to screen drugs rapidly and efficiently, get solid answers, and determine next steps




Informational Webinars about Regimen E

Trehalose/SLS-005 Drug Science and Mechanism of Action Q&A Webinar

Hosted by Seelos Therapeutics on 10 March 2022

Recording Available!





https://bit.ly/3L4hrdB

Recording available under "science and mechanism of action series"


The ALS Association/Northeast ALS Consortium Educational Webinar

Update on Healey ALS Platform Trial Regimen E: Trehalose for ALS

UPDATE ON REGIMEN E

TREHALOSE FOR ALS







BARROW NEUROLOGICAL

TUES | 4 OCTOBER DAY | 3 PM EDT


Recording Available!



https://bit.ly/3X2u004

Recording available under "educational webinars" on neals.org

58 Sites Currently Activated for Regimen E



(as of 12/1/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

	V	Lehigh Valley Health Network	V	<u>UPMC</u>
	V	Mass General Hospital		Indiana University
		University of Kansas	V	Augusta University
	V	University of Maryland	V	University of Utah
		California Pacific Medical Center	V	Holy Cross Hospital
	V	Northwestern University	V	Penn State Hershey
	V	Virginia Commonwealth University	V	University of CA, Irvine
		University of Nebraska	V	Cedars Sinai Medical Center
	V	Washington University	V	University of Pennsylvania
7-1-2		Wake Forest University	V	Nova Southeastern University
14		Hospital for Special Care	V	Johns Hopkins University
al	V	Saint Alphonsus Regional	V	Columbia University
AINE	V	University of Massachusetts	V	Stony Brook University
	V	Duke University	V	Kaiser, Los Angeles
	V	Barrow Neurological Institute	V	Cleveland Clinic
	V	Georgetown University	V	Medical College of Wisconsin
k	V	Texas Neurology	V	University of Michigan

✓ Las Vegas Clinic

George Washington University

Mayo Clinic Florida

University of Kentucky

University of Southern California

Beth Israel Deaconess Medical Center

☑ University of South Florida

University of Colorado

SUNY Upstate

Spectrum Health

Essentia Health

Henry Ford Hospital

Providence Brain and Spine

University of Minnesota

University of Iowa

Swedish Medical Center

Ohio State University

University of Cincinnati

Thomas Jefferson University

UC San Francisco

Mayo Rochester

University of Washington

Vanderbilt University

Site Map & Contacts:



https://bit.ly/3g2NZr5

Enrollment Updates (as of Dec 1, 2022)

• 171 individuals have signed informed consent

127 individuals have been randomized within Regimen E



This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

Patient Navigation Central resource for people living with ALS



Catherine Small



Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:



https://bit.ly/3r6Nd2L

ALS Link sign-up:



https://bit.ly/3o2Ds3m

Upcoming Webinars:

December 8th- Mia Resendes (Primary Coordinator, Mass General Hospital)